JPRN-UMIN000006892招募中未知
Safety and feasibility of coadministration of erlotinib and Theracurmin (nanoparticle curcumin) in patients with advanced or recurrent non-small-cell lung cancer - Safety and feasibility of coadministration of erlotinib and Theracurmin (nanoparticle curcumin) in patients with advanced or recurrent non-small-cell lung cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)idiopathic pulmonary fibrosis, interstitial pneumonia, radiation pneumonitis, drug related pneumonitis 2)plueral, peritoneal, or pericardial effusion requiring drainage 3)active infection 4)unable to take oral medication 5)symptomatic eye disorders 6)pregnant or lactating 7)symptomatic brain metastasis 8)other malignancies 9)uncontrolled diabetes 10) active complications 11)patients whom physicians judged to be unsuitable for enrollment for other reasons
研究者
相似试验
已完成
1 期
Safety evaluation of coadministration of erlotinib and theracurmin in non-small cell lung cancer patientsnon-small cell lung cancerJPRN-UMIN000013424Saitama Medical Center6
进行中（未招募）
不适用
Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Children - Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy ChildreRotaTeq is an oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, G4, and G-serotypes that contain P1 (e.g., G9).MedDRA version: 10Level: LLTClassification code 10017913EUCTR2005-003508-12-DEMerck and Co., Inc.522
进行中（未招募）
不适用
Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Children - Concomitant Use of RotaTeq™ and HEXAVAC® in Healthy ChildreEUCTR2005-003508-12-ATMerck Sharp & Dohme GesmbH
进行中（未招募）
不适用
Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Infants. - Concomitant Use of RotaTeq™ and HEXAVAC® in Healthy ChildreRotaTeq is an oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, G4, and G-serotypes that contain P1 (e.g., G9).MedDRA version: 10Level: LLTClassification code 10017913EUCTR2005-003508-12-BEMerck Sharp & Dohme BV522
尚未招募
2 期
To check safety and efficacy of Naltrexone in advanced esophageal cancer.CTRI/2020/03/023846Tata Memorial Hospital